Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Journal of Cancer Research and Clinical Oncology|July 8, 1998
Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?B Jereczek-Fossa, J Jassem, H Karnicka-Młodkowska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2002
Oral vinorelbine: feasibility and safety profileA Depierre, G Freyer, J Jassem, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative GroupE A Quoix, G Giaccone, J Jassem, et al.
Lung Cancer (Amsterdam, Netherlands)|September 1, 1994
Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancerJ Jassem, H Karnicka-Młodkowska, E Jassem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trialJ Jassem, T Pieńkowski, A Płuzańska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2003
Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancerJ Jassem, P Kosmidis, R Ramlau, et al.
Journal of Cancer Research and Clinical Oncology|July 20, 2005
Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expressionD Dworakowska, E Jassem, J Jassem, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2003
Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferencesM A Nooij, J C J M de Haes, L V A M Beex, et al.
British Journal of Cancer|July 2, 1998
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative GroupM Bontenbal, M Andersson, J Wildiers, et al.
Oncogene|January 7, 1998
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosisJ M de Anta, E Jassem, R Rosell, et al.
Pageof 10